Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials

Jett, J; McLaughlin, M; Wilson, T; Somerville, M; DellaMaestra, W; Rubenstein, D; Piscitelli, S

Piscitelli, S (通讯作者),Dermavant Sci Inc, Morrisville, NC 27560 USA.

JOURNAL OF DRUGS IN DERMATOLOGY, 2022; 21 (10): 1084

Abstract

Background: Tapinarof (VTAMA (R); Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for ps......

Full Text Link